All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Chinese biotech firm Shanghai Henlius Biotech Inc. is taking its PD-L1 antibody known as HLX-20 to Australia to enter a phase I trial for the treatment of advanced solid tumors. The approval from the Australian authorities came six months after Henlius filed the investigational new drug (IND) application for HLX-20 to the China Drug Administration (CDA), and the trial will be the company's first in Australia.